

**07 Jun 2024**

**Bristol-Myers Squibb International Corporation**

**Email: Clinical.Trials@bms.com**

**Chaussée de la Hulpe 185**

**Brussels, Belgium**

**1170**

**EudraCT Number: 2022-000294-67**  
**Sponsor Protocol Number: CA209-6L6**

**Full Official Title:**  
**A Phase II Study of Adjuvant Nivolumab Switch from Intravenous (IV) to Subcutaneous (SC) Use in Participants with Resected Stage III or Stage IV Melanoma or High Risk Invasive Urothelial Carcinoma Originating in the Bladder**

**Trial 2022-000294-67 was withdrawn with 0 patients enrolled. As such no results are reported.**